Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors

Cancer

Volumn 118, Issue 21, 2012, Pages 5310-5319

  Weiss, Glen J ^a,b   Korn, Ronald L ^c  

^a Virginia G Piper Cancer Center   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Scottsdale Medical Imaging   (United States)

Author keywords

computerized tomography; hedgehog signaling pathway; metastatic basal cell carcinoma; nevoid basal cell carcinoma syndrome; positron emission test

Indexed keywords

ANTINEOPLASTIC AGENT; ASCORBIC ACID; BEVACIZUMAB; BMS 833923; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; IXABEPILONE; PACLITAXEL; PAZOPANIB; PEMETREXED; PF 04449913; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SARIDEGIB; SMOOTHENED ANTAGONIST; SONIC HEDGEHOG PROTEIN; SONIDEGIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VISMODEGIB;

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CHEMOSURGERY; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; HUMAN; METASTASIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN SURGERY;

ADOLESCENT; ADULT; AGED; CARCINOMA, BASAL CELL; FEMALE; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84867868105     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27532     Document Type: Review

References (57)

1. Miller DL, Weinstock MA,. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994; 30: 774-778.
2. Malone JP, Fedok FG, Belchis DA, Maloney ME,. Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature. Ear Nose Throat J. 2000; 79: 511-515, 518-519.
3. American Cancer Society Cancer. Facts and Figures, 2011. Available at: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2011. Accessed on July 31, 2011.
4. Ozgediz D, Smith EB, Zheng J, Otero J, Tabatabai ZL, Corvera, CU,. Basal cell carcinoma does metastasize [serial online]. Dermatol Online J. 2008; 14: 5.
5. Grachtchouk M, Pero J, Yang SH, et al. Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations. J Clin Invest. 2011; 121: 1768-1781.
6. McGuire JF, Ge NN, Dyson S,. Nonmelanoma skin cancer of the head and neck. I: histopathology and clinical behavior. Am J Otolaryngol. 2009; 30: 121-133.
7. Chuang TY, Popescu A, Su WP, Chute CG,. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol. 1990; 22: 413-417.
8. Buljan M, Bulat V, Situm M, Mihic LL, Stanic-Dukta JS,. Variations in clinical presentation of basal cell carcinoma. Acta Clin Croat. 2008; 47: 25-30.
9. Reizner GT, Chuang TY, Elpern DJ, Stone JL, Farmer ER,. Basal cell carcinoma in Kauai, Hawaii: the highest documented incidence in the United States. J Am Acad Dermatol. 1993; 29: 184-189.
10. Marks R, Staples M, Giles GG,. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int J Cancer. 1993; 20: 585-590.
11. Hannuksela-Svahn A, Pukkala E, Karvonen J,. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol. 1999; 135: 781-786.
12. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997; 69: 299-308.
13. Lo Muzio L,. Nevoid basal cell carcinoma syndrome (Gorlin syndrome) [serial online]. Orphanet J Rare Dis. 2008; 3: 32.
14. Endo M, Fujii K, Miyashita T, et al. PTCH1 gene analysis in 25 Japanese patients with Gorlin syndrome [article in Japanese]. No To Hattatsu. 2009; 41: 259-263.
15. Tanabe R, Fujii K, Miyashita T, et al. Clinical manifestations in 25 Japanese patients with Gorlin syndrome [article in Japanese]. No To Hattatsu. 2009; 41: 253-257.
16. Kimonis VE, Mehta SG, Digiovanna JJ, Bale SJ, Pastakia B,. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. Genet Med. 2004; 6: 495-502.
17. Palacios E, Serou M, Restrepo S, Rojas R,. Odontogenic keratocysts in nevoid basal cell carcinoma (Gorlin's) syndrome: CT and MRI evaluation. Ear Nose Throat J. 2004; 83: 40-42.
18. Cohen PR, Schulze KE, Nelson BR,. Basal cell carcinoma with mixed histology: a possible pathogenesis for recurrent skin cancer. Dermatol Surg. 2006; 32: 542-551.
19. Crowson AN,. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006; 19: S127-S147.
20. Wadhera A, Fazio M, Bricca G, Stanton O,. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data [serial online]? Dermatol Online J. 2006; 12: 7.
21. Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ,. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991; 24: 715-719.
22. Jahan-Tigh RR, Alston JL, Umphlett M,. Basal cell carcinoma with metastasis to the lung in an African American man. J Am Acad Dermatol. 2010; 63: 87-89.
23. Seo SH, Shim WH, Shin DH, Kim YS, Sung HW,. Pulmonary metastasis of basal cell carcinoma. Ann Dermatol. 2011; 23: 213-216.
24. Lattes R, Kessler RW,. Metastasizing basal-cell epithelioma of the skin; report of 2 cases. Cancer. 1951; 4: 866-878.
25. von Domarus H, Stevens PJ,. Metastatic basal cell carcinoma. Report of 5 cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984; 10: 1043-1060.
26. Corcoran RB, Scott MP,. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc Natl Acad Sci U S A. 2006; 103: 8408-8413.
27. Ting PT, Kasper R, Arlette JP,. Metastatic basal cell carcinoma: report of 2 cases and literature review. J Cutan Med Surg. 2005; 9: 10-15.
28. Fosko SW, Hu W, Cook TF, Lowe VJ,. Positron emission tomography for basal cell carcinoma of the head and neck. Arch Dermatol. 2003; 139: 1141-1146.
29. American Cancer Society. Skin Cancer: Basal and Squamous Cell. Available at: http://www.cancer.org/cancer/skincancer-basalandsquamouscell/detailedguide/ skin-cancer-basal-and-squamous-cell-staging. [Access date.]
30. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 17: 1164-1172.
31. Pan S, Dong Q, Sun LS, Li TJ,. Mechanisms of inactivation of PTCH1 gene in nevoid basal cell carcinoma syndrome: modification of the 2-hit hypothesis. Clin Cancer Res. 2010; 15: 442-450.
32. Chinem VP, Miot HA,. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011; 86: 292-305.
33. Weiss GJ, Von Hoff DD,. Hunting the hedgehog pathway. Clin Pharmacol Ther. 2010; 87: 743-747.
34. Binns W, James LF, Shupe JL, Thacker EJ,. Cyclopian-type malformation in lambs. Arch Environ Health. 1962; 5: 106-108.
35. Binns W, James LF, Shupe JL, Everett G,. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum californicum. Am J Vet Res. 1963; 24: 1164-1175.
36. Keeler RF, Binns W,. Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources. Teratology. 1968; 1: 5-10.
37. Lum L, Beachy PA,. The hedgehog response network: sensors, switches, and routers. Science. 2004; 18: 1755-1759.
38. Ma Y, Erkner A, Gong R, et al. Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched. Cell. 2002; 4: 63-75.
39. Cooper MK, Porter JA, Young KE, Beachy PA,. Teratogen-mediated inhibition of target tissue response to shh signaling. Science. 1998; 5: 1603-1607.
40. Epstein EH,. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008; 8: 743-754.
41. Scales SJ, de Sauvage FJ,. Mechanisms of hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009; 30: 303-312.
42. Ingham PW, Placzek M,. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat Rev Genet. 2006; 7: 841-850.
43. Pfeiffer P, Hansen O, Rose C,. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer. 1990; 26: 73-77.
44. Wieman TJ, Shively EH, Woodcock TM,. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer. 1983; 52: 1583-1585.
45. Jefford M, Kiffer JD, Somers G, Daniel FJ, Davis ID,. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004; 74: 704-705.
46. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE,. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006; 24: 396-400.
47. National Institutes of Health. National clinical trials website. Available at: http://www.clinicaltrials.gov. Accessed December 16, 2011.
48. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011; 17: 2502-2511.
49. Sekulic A, Migden MR, Oro AE, et al. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). Paper presented at: Seventh European Association of Dermato-Oncology (EADO) Congress; June 20-23, 2011; Nantes, France. Abstract C014.
50. Tawbi HA, Ahnert JR, Dummer R, et al. Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 3062.
51. So PL, Tang JY, Epstein EH,. Novel investigational drugs for basal cell carcinoma. Expert Opin Investig Drugs. 2010; 19: 1099-1112.
52. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP,. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion [serial online]. PLoS Biol. 2006; 4: e232.
53. Mazumdar T, Devecchio J, Agyeman A, Shi T, Houghton JA,. Blocking hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res. 2011; 71: 5904-5914.
54. Beauchamp EM, Ringer L, Bulut G, et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J Clin Invest. 2011; 4: 148-160.
55. Lauth M, Rohnalter V, Bergstrom A, Kooshesh M., Svenningsson P, Toftgard R Antipsychotic drugs regulate hedgehog signaling by modulation of 7-dehydrocholesterol reductase levels. Mol Pharmacol. 2010; 78: 486-496.
56. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010; 17: 388-399.
57. Rudin CM, Jimeno A, Miller WH, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 3014.